BiotechTube
NKILT Therapeutics

NKILT Therapeutics

Cambridge, United States· Est.
nkilt.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NKILT Therapeutics is an early-stage biotech pioneering a unique approach to cell therapy by targeting the HLA-G checkpoint via engineered NK cells. Its core CIR™ platform is designed to leverage natural receptor binding for specificity and enhanced signaling, with potential application across over 50% of cancers. Founded in 2020/2021 and based in Cambridge, MA, the company is in pre-clinical development, building a team with deep oncology and cell therapy experience to advance its off-the-shelf therapies toward the clinic.

Oncology

Technology Platform

Proprietary Chimeric ILT-Receptor (CIR™) platform for engineering immune cells. It uses a natural receptor (ILT) binding domain to target the HLA-G immune checkpoint, combined with an optimized signaling domain, initially applied to create allogeneic, off-the-shelf Natural Killer (NK) cell therapies.

Opportunities

The broad expression of HLA-G across >50% of cancers presents a large addressable patient population.
The shift towards allogeneic, off-the-shelf cell therapies creates a major market opportunity for scalable, accessible, and potentially lower-cost treatments compared to autologous therapies.
Success in solid tumors, where current cell therapies have largely failed, would be a transformative breakthrough.

Risk Factors

The novel CIR™ technology is unproven in humans and faces significant scientific risk regarding efficacy, safety (potential on-target toxicity), and manufacturability.
The company is at a very early, pre-clinical stage with limited disclosed data and is dependent on securing additional funding.
It operates in an intensely competitive landscape of well-funded allogeneic cell therapy companies.

Competitive Landscape

NKILT competes in the crowded and rapidly evolving field of allogeneic cell therapy, particularly against companies developing engineered NK cell platforms (e.g., Fate Therapeutics, Nkarta, Century Therapeutics, Artiva Biotherapeutics). Its differentiation hinges on the unique HLA-G target and its natural receptor-based CIR™ engineering approach, which is distinct from most CAR-based platforms.

More companies in Cell & Gene Therapy →More companies in United States →